*** On mobile devices , use left and right swipe gestures to view whole agenda
| Time | Session | Novel Targets | Lead Optimisation & Modality | Translational & Preclinical | Endpoints, Biomarkers & Outcomes |
|---|---|---|---|---|---|
| 08:00 – 08:30 | Registration & Welcome Coffee | ||||
| 08:30 – 09:00 |
Welcome & Keynote Presentation
The Cardiometabolic Era: How Obesity Therapeutics Are Reshaping
Cardiovascular Drug Development
|
||||
| Breakout Sessions | |||||
| 09:05 – 10:05 | Session 1 |
Novel Targets
End-user Roundtable: Validating novel targets beyond
incretin biology using human genetic and clinical data
|
Lead Optimisation & Modality
End-user Roundtable: Selecting the optimal modality
for complex and previously undruggable cardiometabolic targets
|
Translational & Preclinical
End-user Roundtable: Improving the predictive value
of obesity and cardiovascular preclinical models
|
Endpoints, Biomarkers & Outcomes
End-user Roundtable: Measuring weight quality
through lean-mass preservation, fat distribution and body
composition
|
| Moderator | |||||
| 10:10 – 10:40 | Sponsor 1:1 Sessions / Peer-to-Peer Networking | ||||
| 10:40 – 11:10 | Sponsor 1:1 Sessions / Peer-to-Peer Networking | ||||
| 11:10 – 11:20 | Morning Refreshments | ||||
| 11:20 – 12:20 | Session 2 |
Novel Targets
Sponsor-led Roundtable: Mechanisms addressing
obesity-related cardiovascular and renal complications
|
Lead Optimisation & Modality
Sponsor-led Roundtable: Balancing potency,
selectivity and tolerability during lead optimisation
|
Translational & Preclinical
Sponsor-led Roundtable: Translating weight loss,
body composition and metabolic effects from animals to humans
|
Endpoints, Biomarkers & Outcomes
Sponsor-led Roundtable: Early biomarkers predicting
long-term cardiovascular and metabolic benefit
|
| Moderator | |||||
| 12:20 – 13:20 | Lunch | ||||
| 13:20 – 13:50 |
Spotlight Presentation
Featured Cardiometabolic & Obesity Therapeutics Presentation
|
||||
| 13:55 – 14:25 | Sponsor 1:1 Sessions / Peer-to-Peer Networking | ||||
| 14:25 – 14:55 | Sponsor 1:1 Sessions / Peer-to-Peer Networking | ||||
| 15:00 – 15:30 | Session 3 |
Case Study – Novel Targets
Targets with durable efficacy and limited compensatory biology
|
Case Study – Lead Optimisation & Modality
Orally available therapies with competitive dosing and exposure
|
Case Study – Translational & Preclinical
Modelling comorbidities and heterogeneous patient populations
|
Case Study – Endpoints, Biomarkers & Outcomes
Endpoints beyond total weight loss to demonstrate differentiation
|
| Moderator | |||||
| 15:35 – 16:35 | Session 4 |
Novel Targets
End-user Roundtable: Differentiating new targets in
a crowded cardiometabolic pipeline
|
Lead Optimisation & Modality
End-user Roundtable: Optimising combination,
multi-agonist and multi-mechanism approaches
|
Translational & Preclinical
End-user Roundtable: Establishing translational
biomarkers and exposure-response before clinical entry
|
Endpoints, Biomarkers & Outcomes
End-user Roundtable: Designing efficient
cardiovascular, renal and metabolic outcomes trials
|
| Moderator | |||||
| 16:35 – 17:35 | Evening Drinks Reception | ||||
